Loading comparison data...
Compare Risankizumab (Skyrizi) and Tofacitinib (Xeljanz) — clinical data, side effects, and patient experiences.
Skyrizi · Biologic (IL-23 Inhibitor)
How it works
Humanized monoclonal antibody that selectively binds to the p19 subunit of IL-23, inhibiting IL-23-dependent inflammatory signalling.
Approved for
Xeljanz · JAK Inhibitor
How it works
Inhibits Janus kinases JAK1 and JAK3, modulating the signalling of interleukins and interferons involved in immune and inflammatory pathways.
Approved for
Estimated frequency (%) based on clinical trial data
No head-to-head clinical studies found for Risankizumab vs Tofacitinib.
Risankizumab is a Biologic (IL-23 Inhibitor), while Tofacitinib belongs to the JAK Inhibitor class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. Risankizumab is administered via Subcutaneous, whereas Tofacitinib uses Oral. Route of administration can affect onset of action and patient adherence.
Both medications are approved for Psoriatic Arthritis. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.
Risankizumab carries 2 FDA warnings. Tofacitinib carries 2 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.
Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.